Centro Médico Fleischer

Centro Médico Fleischer
CABA, C1414
Select an option
Open studies
Breast Cancer
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) - VIKTORIA-1 - Celcuity, Inc.See more
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) - CAPItello-292 - AstraZenecaSee more
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer - TROPION-Breast05 - AstraZenecaSee more
Lung cancer
Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer - KontRASt-02 - Novartis PharmaceuticalsSee more
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer - GlaxoSmithKlineSee more
Leukemia
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010) - BELLWAVE-010 - Merck Sharp & Dohme LLCSee more
Non-Hodgkin Lymphoma
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010) - BELLWAVE-010 - Merck Sharp & Dohme LLCSee more
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy